Indications
Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or kneereplacement surgery. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)
Composition
- Active substance
- rivaroxaban
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Rivaroxaban Koanaa
- Active substance
- rivaroxaban
- ATC code
- B01AF01
- Therapeutic area
- Venous Thromboembolism, Pulmonary Embolism, Venous Thrombosis, Stroke, Embolism
- Marketing authorisation holder